Examine the complementary effects of omega lipid on lipid profile serum and compare it with effect of placebo of omega in patients With Chronic dialysis.

Evaluation of the effect of omega-3 supplimentation on serum lipid in patients with chronic dialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014112520087N1

Enrollment

Registered

2015-05-24

Start date

2014-12-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease. Chronic kidney disease

Interventions

Intervention 1: Control: Daily one placebo of Omega Max made in Zahravi Pharmaceutical Company for three months Prescribed. Intervention 2: Intervention group: Daily one Omega Max Capsule made in Zahr

Placebo

Prevention

Control: Daily one placebo of Omega Max made in Zahravi Pharmaceutical Company for three months Prescribed.

Intervention group: Daily one Omega Max Capsule made in Zahravi Pharmaceutical Company containing 400 mg Eicosapentanoic Acid and 300 mg Decosa Hexanoic Acid for three months prescribed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients that have been receive dialysis therapy for more than three months? patients that have been received no anti-lipid drugs as yet. Exclusion criteria for the study: Patients that can’t tolerate drugs receive? patients not interested in drugs receive? patients die during intervention.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
High Density Lipoprotein (HDL). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum HDL concentrations in scale mili mol / lit.;Low Density Lipoprotein (lDL). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum LDL concentrations in scale mili mol / lit.;Triglyceride(TG). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum TG concentrations in scale mili mol / lit.	—

Measure

Time frame

High Density Lipoprotein (HDL). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum HDL concentrations in scale mili mol / lit.;Low Density Lipoprotein (lDL). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum LDL concentrations in scale mili mol / lit.;Triglyceride(TG). Timepoint: Before and three months after intervention. Method of measurement: Laboratory measurement of serum TG concentrations in scale mili mol / lit.

—

Secondary

Measure	Time frame
Cross Reacting Protein (CRP). Timepoint: Before intervention, three months after intervention. Method of measurement: Laboratory measurement of serum CRP concentrations in scale Mg / dl.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Bahman Bashardoost

Ardabil University of Medical Sciences

bahman.bashardoost@arums.ac.ir+98 45332514018

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026